Funding Opportunity PAR-25-156 from the NIH Guide for Grants and Contracts. The purpose of the High Impact Specialized Innovation Programs (SIPs) is to support the development and demonstration of unique hub capabilities, research platforms and/or resources to address in a timely manner critical gap areas and/or roadblocks in clinical and translational science at awarded UM1 Clinical and Translational Science Awards (CTSA) Program Hubs (PAR-24-272). Successful programs supported through this funding opportunity are expected to lay a strong foundation for future adoption and/or dissemination of capabilities to additional CTSA Program Hubs.

Funding Opportunity PAR-25-196 from the NIH Guide for Grants and Contracts. The National Center for Advancing Translational Sciences (NCATS) will award Institutional Research Career Development (K12) programs through the Clinical and Translational Science Awards (CTSA). The purpose of this Notice of Funding Opportunity (NOFO) is to encourage institutions to propose creative and innovative institutional research career development programs designed to prepare an outstanding heterogeneous pool of promising later stage postdoctoral fellows and junior faculty scholars who have made a commitment to independent clinical and translational science research careers (i.e., tenure-track or equivalent faculty positions)to facilitate their timely career advancementand continued engagement in research (i.e., sectors including academia, industry, nonprofit and government).

Funding Opportunity RFA-RM-24-010 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to establish Comprehensive NAMs Technology Development Centers to support NIH Common Funds Complement Animal Research In Experimentation (Complement-ARIE) program. The Complement-ARIE program will accelerate the development, standardization, validation, and use of human-based New Approach Methodologies (NAMs). Complement-ARIE will significantly advance understanding of human health and disease by providing a range of mature and/or validated and standardized biomedical research models. The goal of the Comprehensive NAMs Technology Development Centers is to stimulate the development of combinatorial NAMs to support scientific areas of need, with emphasis on increased biological complexity and throughput, innovative combinatorial approaches, and data sharing according to FAIR principles. Developing these NAMs will require multi-disciplinary expertise in disease research, personalized medicine, screening therapeutics for safety and efficacy, and regulatory science.

Funding Opportunity PAR-25-309 from the NIH Guide for Grants and Contracts. This PAR seeks applications from eligible Small Business Concerns (SBCs) for the development of informatics tools with commercial potential to facilitate uptake and scientific use of the human pangenome reference being developed and maintained by the NHGRI Human Genome Reference Program (HGRP). This PAR specifically calls for innovative Phase I STTR applications from SBCs to demonstrate proof of principle or viability of informatics tools for use of the human pangenome. Emphasis will be on the development of tools to advance compelling use cases that are relevant to different broad sectors of the genomics community, e.g., clinical, population, and functional genomics.

Funding Opportunity PAR-25-308 from the NIH Guide for Grants and Contracts. This PAR seeks applications from eligible Small Business Concerns (SBCs) for the development of informatics tools with commercial potential to facilitate uptake and scientific use of the human pangenome reference being developed and maintained by the NHGRI Human Genome Reference Program (HGRP). This PAR specifically calls for innovative Phase I SBIR applications from SBCs to demonstrate proof of principle or viability of informatics tools for use of the human pangenome. Emphasis will be on the development of tools to advance compelling use cases that are relevant to different broad sectors of the genomics community, e.g., clinical, population, and functional genomics.

Funding Opportunity RFA-AG-25-001 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications that aim to develop Common Data Elements (CDEs) for NIA-funded studies on Alzheimers disease (AD) and AD-Related Dementias (ADRD) using Real-World Data (RWD) from electronic health records and claims data from Centers for Medicare and Medicaid Services (CMS). The CDEs will foster data harmonization and interoperability across and among NIA studies that involve disparate and unaligned data fields and RWD. By reducing the efforts required for data harmonization in using studies and RWD for cross-sectional and longitudinal analysis, this NOFO may enable researchers to utilize studies data and RWD more efficiently and produce real-world evidence (RWE) in a timely manner with longitudinal data from NIA-funded studies and RWD.

Funding Opportunity RFA-AG-25-015 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to invite applications for the Coordination Center for the Alzheimers Disease Sequencing Project (ADSP) consortium. The ADSP Coordination Center will provide leadership and technical expertise in all aspects of ADSP research. The ADSP Coordination Center will lead and coordinate cross-consortium functions, including effective communication, collaboration, outreach, dissemination, training, and coordination across the components of the ADSP. In addition, the ADSP Coordination Center will be the main conduit for collaboration with NIH and NIA funded programs and the global research community in the genetics and genomics of Alzheimers disease and Alzheimers disease-related dementias (AD/ADRD).

Funding Opportunity PAR-24-289 from the NIH Guide for Grants and Contracts. This Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed) PAR, a re-issue of PAR-23-025, was re-issued as a result of the Simplifying Review of Research Project Grant Applications [link: https://grants.nih.gov/policy-and-compliance/policy-topics/peer-review/simplifying-review]. The Simplified Review changes in Section V are the only changes that have been made. All other aspects of this funding opportunity remain the same.

Notice NOT-OD-25-044 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-24-287 from the NIH Guide for Grants and Contracts. This Limited Competition: Small Grant Program for NIAMS K01, K08, K23, and K25 Recipients (R03), a re-issue of PAR-22-119, was re-issued as a result of the Simplifying Review of Research Project Grant Applications [link: https://grants.nih.gov/policy-and-compliance/policy-topics/peer-review/simplifying-review]. The Simplified Review changes in Section V are the only changes that have been made. All other aspects of this funding opportunity remain the same.

Funding Opportunity PAR-25-230 from the NIH Guide for Grants and Contracts. This Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed) PAR, a re-issue of PAR-23-026, was re-issued as a result of the Simplifying Review of Research Project Grant Applications [link: https://grants.nih.gov/policy-and-compliance/policy-topics/peer-review/simplifying-review]. The Simplified Review changes in Section V are the only changes that have been made. All other aspects of this funding opportunity remain the same.

Funding Opportunity PAR-25-197 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs.

Funding Opportunity PAR-25-330 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support research to define the impact of defective HIV proviruses on mechanisms of HIV persistence and pathogenesis during antiretroviral treatment and their potential deleterious effects on HIV cure strategies and interference with HIV-specific molecular assays.

Notice NOT-OD-25-028 from the NIH Guide for Grants and Contracts

Notice NOT-AG-24-063 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-141 from the NIH Guide for Grants and Contracts. This NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required) PAR, a re-issue of PAR-24-208, was re-issued as a result of the Simplifying Review of Research Project Grant Applications [link: https://grants.nih.gov/policy-and-compliance/policy-topics/peer-review/simplifying-review]. The Simplified Review changes in Section V. Application Review Information of the funding opportunity are the only changes that have been made. All other aspects of this funding opportunity remain the same.

Funding Opportunity PAR-24-280 from the NIH Guide for Grants and Contracts. This Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed) PAR, was re-issued as a result of the Simplifying Review of Research Project Grant Applications [link: https://grants.nih.gov/policy-and-compliance/policy-topics/peer-review/simplifying-review]. The Simplified Review changes in Section V are the only changes that have been made. All other aspects of this funding opportunity remain the same.

Funding Opportunity PAR-24-279 from the NIH Guide for Grants and Contracts. This Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required) PAR, a re-issue of PAR-24-035, was re-issued as a result of the Simplifying Review of Research Project Grant Applications [link: https://grants.nih.gov/policy-and-compliance/policy-topics/peer-review/simplifying-review]. The Simplify Review changes in Section V are the only changes that have been made. All other aspects of this funding opportunity remain the same.

Funding Opportunity RFA-EY-25-001 from the NIH Guide for Grants and Contracts. A central goal of the BRAIN Initiative is to understand how electrical and chemical signals code information in neural circuits and give rise to sensations, thoughts, emotions and actions. While currently available technologies can provide some understanding, they may not be sufficient to accomplish this goal. For example, non-invasive technologies are low resolution and/or provide indirect measures such as blood flow, which are imprecise; invasive technologies can provide information at the level of single neurons producing the fundamental biophysical signals, but they can only be applied to tens or hundreds of neurons, out of a total number in the human brain estimated at 85 billion. Other BRAIN FOAs seek to develop novel technology (RFA-NS-17-003) or to optimize existing technology ready for in-vivo proof-of-concept testing and collection of preliminary data (RFA-NS-17-004) for recording or manipulating neural activity on a scale that is beyond what is currently possible. This FOA seeks applications for unique and innovative technologies that are in an even earlier stage of development than that sought in other FOAs, including new and untested ideas that are in the initial stages of conceptualization. In addition to experimental approaches, the support provided under this FOA might enable calculations, simulations, computational models, or other mathematical techniques for demonstrating that the signal sources and/or measurement technologies are theoretically capable of meeting the demands of large-scale recording or manipulation of circuit activity in humans or in animal models. The support might also be used for building and testing phantoms, prototypes, in-vitro or other bench-top models in order to validate underlying theoretical assumptions in preparation for future FOAs aimed at testing in animal models.

Funding Opportunity RFA-MD-24-011 from the NIH Guide for Grants and Contracts. NIMHD invites applications from eligible institutions to establish a national coordinating center (CC) for NIMHD-funded Research Centers in Minority Institutions (RCMIs). The RCMI CC will work closely with key personnel at all RCMI Specialized Centers and with NIMHD staff to help the centers collectively achieve their objectives to: (1) enhance institutional research capacity within the areas of basic biomedical, behavioral, and/or clinical research (patient-oriented and health services research); (2) enable all levels of investigators to become more successful in obtaining competitive extramural support, especially from NIH, particularly on diseases that disproportionately impact minority and other health disparity populations; (3) foster environments conducive to career enhancement with a special emphasis on development of early career investigators; (4) enhance the quality of all scientific inquiry and promote research on minority health and health disparities; (5) establish sustainable relationships with community-based organizations that partner with RCMI centers, and (6) centralize and harmonize study operations, coordinate data management, provide biostatistical support to facilitate rapid development and implementation of minority health and health disparity studies conducted in the RCMI-CRNHE (Clinical Research Network for Health Equity) (see RFA-MD-22-006), and also manage a Network Steering Committee . The RCMI CC will be responsive to requests generated by RCMI site key personnel, NIMHD, NIH, the scientific community, and the general public. Eligible applicant institutions for this FOA are limited to recipients of RCMI awards through RFA-MD-17-003, RFA-MD-17-006, RFA-MD-18-012, RFA-MD-20-006, PAR-11-132, RFA-MD-22-002, RFA-MD-23-001, or RFA-MD-24-001.